人乳头瘤病毒相关口咽癌治疗的减量化：现状与未来方向。
Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.
机构信息
Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Oncology, Johns Hopkins University, Baltimore, MD, United States.
出版信息
Oral Oncol. 2020 Jun;105:104652. doi: 10.1016/j.oraloncology.2020.104652. Epub 2020 Apr 2.
Abstract
Human papillomavirus (HPV)-related oropharyngeal squamous cell cancer (OPSCC) has emerged as a distinct clinical entity of head and neck cancer with expected high survival. This recognition has led to the investigation of whether a population of patients can be identified who can safely undergo treatment de-escalation, in an effort to minimize long-term treatment toxicity while maintaining excellent survival. The purpose of this review is to describe the rationale for treatment deintensification for HPV-related OPSCC, summarize available results from published clinical trials, explore the methods by which risk groups are assigned, and provide context for the multitude of clinical trials that are currently underway.
摘要
人乳头瘤病毒（HPV）相关口咽鳞状细胞癌（OPSCC）已成为头颈部癌症的一个独特临床实体，预计具有较高的生存率。这种认识促使人们研究是否可以确定一类患者可以安全地进行治疗降级，以努力降低长期治疗毒性，同时保持良好的生存。本文综述的目的是描述 HPV 相关 OPSCC 治疗减量化的原理，总结已发表临床试验的结果，探讨风险组分配的方法，并为目前正在进行的大量临床试验提供背景。
相似文献
1
Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.人乳头瘤病毒相关口咽癌治疗的减量化：现状与未来方向。
Oral Oncol. 2020 Jun;105:104652. doi: 10.1016/j.oraloncology.2020.104652. Epub 2020 Apr 2.
2
Treatment preferences in human papillomavirus-associated oropharyngeal cancer.人乳头瘤病毒相关性口咽癌的治疗偏好。
Future Oncol. 2018 Oct;14(24):2521-2530. doi: 10.2217/fon-2018-0063. Epub 2018 Sep 28.
3
Clinical features and treatment strategy for HPV-related oropharyngeal cancer.人乳头瘤病毒相关口咽癌的临床特征与治疗策略
Int J Clin Oncol. 2016 Oct;21(5):827-835. doi: 10.1007/s10147-016-1009-6. Epub 2016 Jul 5.
4
Postoperative Radiation Therapy Refusal in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.人乳头瘤病毒相关口咽鳞状细胞癌术后拒绝放疗。
Laryngoscope. 2022 Feb;132(2):339-348. doi: 10.1002/lary.29743. Epub 2021 Jul 13.
5
Human papillomavirus-related oropharyngeal cancer.人乳头瘤病毒相关性口咽癌。
Ann Oncol. 2017 Oct 1;28(10):2386-2398. doi: 10.1093/annonc/mdx304.
6
Current Status and Future Directions of Treatment Deintensification in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma.人乳头瘤病毒相关口咽鳞状细胞癌治疗减量化的现状与未来方向。
Semin Radiat Oncol. 2018 Jan;28(1):27-34. doi: 10.1016/j.semradonc.2017.08.001.
7
Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas.人乳头瘤病毒状态对非口咽头颈鳞状细胞癌患者的预后影响
J Cancer Res Clin Oncol. 2017 Nov;143(11):2341-2350. doi: 10.1007/s00432-017-2481-8. Epub 2017 Jul 27.
8
Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma.单纯放疗作为人乳头瘤病毒相关局部晚期口咽鳞状细胞癌可能的减量化治疗。
Int J Clin Oncol. 2019 Jun;24(6):640-648. doi: 10.1007/s10147-019-01394-1. Epub 2019 Jan 29.
9
Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.比较 HPV 阳性口咽鳞状细胞癌的标准剂量放疗与降低放疗剂量在确定性治疗中的作用。
Radiother Oncol. 2019 May;134:81-88. doi: 10.1016/j.radonc.2019.01.016. Epub 2019 Feb 4.
10
The evolving landscape of human papillomavirus-related oropharyngeal squamous cell carcinoma at a single institution in Northern Italy.意大利北部一家机构中与人类乳头瘤病毒相关的口咽鳞状细胞癌的演变情况
Acta Otorhinolaryngol Ital. 2019 Feb;39(1):9-17. doi: 10.14639/0392-100X-1905.
引用本文的文献
1
Prognostic analysis of inconsistent combinations of HPV and p16 in a Chinese/Asian oropharyngeal squamous cell carcinoma population.中国/亚洲口咽鳞状细胞癌人群中HPV与p16不一致组合的预后分析
Infect Agent Cancer. 2025 Jun 9;20(1):35. doi: 10.1186/s13027-025-00657-z.
2
A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.一种新型 ΔNp63 依赖性免疫机制改善 HPV 相关头颈部癌症的预后。
Front Immunol. 2023 Oct 25;14:1264093. doi: 10.3389/fimmu.2023.1264093. eCollection 2023.
3
Assessment of Radiologic Extranodal Extension Using Combinatorial Analysis of Nodal Margin Breakdown and Metastatic Burden in Oropharyngeal Cancer.利用口咽癌淋巴结边缘分解和转移负荷的组合分析评估放射学结外扩展
Cancers (Basel). 2023 Jun 21;15(13):3276. doi: 10.3390/cancers15133276.
4
Spatially-aware clustering improves AJCC-8 risk stratification performance in oropharyngeal carcinomas.空间感知聚类可提高口咽癌 AJCC-8 风险分层性能。
Oral Oncol. 2023 Sep;144:106460. doi: 10.1016/j.oraloncology.2023.106460. Epub 2023 Jun 28.
5
Unsupervised Hierarchical Clustering of Head and Neck Cancer Patients by Pre-Treatment Plasma Metabolomics Creates Prognostic Metabolic Subtypes.通过治疗前血浆代谢组学对头颈癌患者进行无监督分层聚类可创建预后代谢亚型。
Cancers (Basel). 2023 Jun 14;15(12):3184. doi: 10.3390/cancers15123184.
6
Transoral Surgery in HPV-Positive Oropharyngeal Carcinoma: Oncologic Outcomes in the Veterans Affairs System.经口手术治疗 HPV 阳性口咽癌：退伍军人事务系统的肿瘤学结局。
Laryngoscope. 2024 Jan;134(1):207-214. doi: 10.1002/lary.30784. Epub 2023 May 31.
7
EGFR-induced suppression of HPV E6/E7 is mediated by microRNA-9-5p silencing of BRD4 protein in HPV-positive head and neck squamous cell carcinoma.EGFR 诱导的 HPV E6/E7 抑制是通过 microRNA-9-5p 沉默 HPV 阳性头颈部鳞状细胞癌中的 BRD4 蛋白介导的。
Cell Death Dis. 2022 Nov 4;13(11):921. doi: 10.1038/s41419-022-05269-8.
8
The accuracy of clinical neck staging for p16-positive and negative oropharyngeal cancer and its therapeutic implications.p16 阳性和阴性口咽癌的临床颈部分期准确性及其治疗意义。
Eur Arch Otorhinolaryngol. 2022 Nov;279(11):5339-5345. doi: 10.1007/s00405-022-07430-7. Epub 2022 Jul 4.
9
Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.头颈部癌症（包括唾液腺癌）标志物应用的推荐：西班牙肿瘤内科学会和西班牙病理学会的共识。
Clin Transl Oncol. 2022 Oct;24(10):1890-1902. doi: 10.1007/s12094-022-02856-1. Epub 2022 Jun 23.
10
The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review.头颈部癌症的变化面貌：人乳头瘤病毒阳性疾病患者的营养风险更高吗？一项系统评价。
Support Care Cancer. 2022 Sep;30(9):7191-7204. doi: 10.1007/s00520-022-07056-9. Epub 2022 Apr 27.
本文引用的文献
1
Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.HPV 相关口咽鳞状细胞癌放疗与经口手术降阶梯治疗（ORATOR2）：一项随机 II 期试验的研究方案。
BMC Cancer. 2020 Feb 14;20(1):125. doi: 10.1186/s12885-020-6607-z.
2
A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus-Related Squamous Cell Carcinoma of the Oropharynx.一项针对口咽鳞癌调强放疗减容的替代容积的 2 期临床试验（AVOID）：经口机器人手术后人乳头瘤病毒相关口咽鳞癌切除原发肿瘤床的省略。
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):725-732. doi: 10.1016/j.ijrobp.2019.11.021. Epub 2019 Nov 27.
3
Immunotherapy for head and neck cancer: Recent advances and future directions.头颈部癌症的免疫治疗：最新进展和未来方向。
Oral Oncol. 2019 Dec;99:104460. doi: 10.1016/j.oraloncology.2019.104460. Epub 2019 Nov 1.
4
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.放疗与经口机器人手术和颈部清扫术治疗口咽鳞状细胞癌（ORATOR）：一项开放标签、2 期、随机试验。
Lancet Oncol. 2019 Oct;20(10):1349-1359. doi: 10.1016/S1470-2045(19)30410-3. Epub 2019 Aug 12.
5
Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.人乳头瘤病毒相关口咽鳞状细胞癌去强化放化疗的 II 期临床试验。
J Clin Oncol. 2019 Oct 10;37(29):2661-2669. doi: 10.1200/JCO.19.01007. Epub 2019 Aug 14.
6
Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.诱导化疗后 HPV+口咽癌患者的标准治疗与低剂量放化疗：四分卫试验。
Oral Oncol. 2019 Aug;95:170-177. doi: 10.1016/j.oraloncology.2019.06.021. Epub 2019 Jun 25.
7
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.人乳头瘤病毒相关口咽鳞状细胞癌辅助放化疗强化剂量降阶的 II 期评估。
J Clin Oncol. 2019 Aug 1;37(22):1909-1918. doi: 10.1200/JCO.19.00463. Epub 2019 Jun 4.
8
Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion.p16+ 口咽癌治疗减量化的作用：ASCO 临时临床观点。
J Clin Oncol. 2019 Jun 20;37(18):1578-1589. doi: 10.1200/JCO.19.00441. Epub 2019 Apr 25.
9
Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer.放射学结外侵犯预示着 cN+TNM-8 期 HPV 相关口咽癌预后更差。
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1017-1027. doi: 10.1016/j.ijrobp.2019.03.047. Epub 2019 Apr 4.
10
Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.NRG 肿瘤学/RTOG-0129 风险组在 HPV 阳性和 HPV 阴性口咽鳞状细胞癌中的验证：对基于风险的治疗强度试验的影响。
Cancer. 2019 Jun 15;125(12):2027-2038. doi: 10.1002/cncr.32025. Epub 2019 Mar 26.
Zotero 插件